JP6730183B2 - シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ） - Google Patents

シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ） Download PDF

Info

Publication number
JP6730183B2
JP6730183B2 JP2016524705A JP2016524705A JP6730183B2 JP 6730183 B2 JP6730183 B2 JP 6730183B2 JP 2016524705 A JP2016524705 A JP 2016524705A JP 2016524705 A JP2016524705 A JP 2016524705A JP 6730183 B2 JP6730183 B2 JP 6730183B2
Authority
JP
Japan
Prior art keywords
group
formula
alkyl
cystobactamide
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016524705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527215A5 (OSRAM
JP2016527215A (ja
Inventor
バウマン，サッシャ
ヘルマン，ジェニファー
モール，カトリン
シュタインメッツ，ハインリヒ
ゲース，クラウス
ラジュ，リテシュ
ミュラー，ロルフ
ハートマン，ロルフ
ハメド，モスタファ
エー エム エルガエール，ウァリド
エー エム エルガエール，ウァリド
モレノ，マリア
ジリー，フランツィスカ
リャン ワン，リャン
リャン ワン，リャン
カーシュニング，アンドレアス
ヒューテル，ステファン
Original Assignee
ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー
ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー, ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー filed Critical ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー
Publication of JP2016527215A publication Critical patent/JP2016527215A/ja
Publication of JP2016527215A5 publication Critical patent/JP2016527215A5/ja
Application granted granted Critical
Publication of JP6730183B2 publication Critical patent/JP6730183B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
JP2016524705A 2013-07-12 2014-07-14 シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ） Active JP6730183B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003539.7 2013-07-12
EP13003539 2013-07-12
PCT/EP2014/001925 WO2015003816A2 (en) 2013-07-12 2014-07-14 Cystobactamides

Publications (3)

Publication Number Publication Date
JP2016527215A JP2016527215A (ja) 2016-09-08
JP2016527215A5 JP2016527215A5 (OSRAM) 2017-08-03
JP6730183B2 true JP6730183B2 (ja) 2020-07-29

Family

ID=48792948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524705A Active JP6730183B2 (ja) 2013-07-12 2014-07-14 シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ）

Country Status (7)

Country Link
US (3) US20160145304A1 (OSRAM)
EP (1) EP3019615B1 (OSRAM)
JP (1) JP6730183B2 (OSRAM)
CN (1) CN105793424B (OSRAM)
AU (1) AU2014289663B2 (OSRAM)
CA (1) CA2917767C (OSRAM)
WO (1) WO2015003816A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6730183B2 (ja) 2013-07-12 2020-07-29 ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ）
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
WO2015174747A1 (ko) * 2014-05-15 2015-11-19 한국생명공학연구원 신규한 항균성 화합물 및 이의 용도
WO2016082934A1 (en) * 2014-11-26 2016-06-02 Helmholtz-Zentrum für Infektionsforschung GmbH Novel cystobactamides
CN105712894A (zh) * 2016-03-23 2016-06-29 叶芳 一种3-甲氧基-4-氨基苯甲酸及其制备方法
JP7037122B2 (ja) * 2016-09-28 2022-03-16 日産化学株式会社 ジアミンおよびその利用
JP7277431B2 (ja) 2017-07-11 2023-05-19 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのカルボキサミド
EP3655394B1 (en) 2017-07-18 2023-11-22 Technische Universität Berlin Novel albicidin derivatives, their use and synthesis
JP7244493B2 (ja) * 2017-08-23 2023-03-22 ヘルムホルツ－ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー 新規なシストバクタミド誘導体
US11247987B2 (en) 2017-10-06 2022-02-15 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
WO2019139900A1 (en) 2018-01-10 2019-07-18 Zeno Royalties & Milestones, LLC Benzamide compounds
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
WO2022212080A1 (en) * 2021-03-31 2022-10-06 Medibeacon Inc. Purification of substituted diaminopyrazine dicarboxylic acids
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
CN113563220B (zh) * 2021-06-25 2023-08-29 华中农业大学 一种抗菌化合物及其应用
WO2025003147A1 (en) 2023-06-26 2025-01-02 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamid derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525354A (en) * 1983-09-14 1985-06-25 University Of Hawaii Antibiotic and process for the production thereof
US7020622B1 (en) * 1997-06-10 2006-03-28 Linkshare Corporation Transaction tracking, managing, assessment, and auditing data processing system and network
FR2772025B1 (fr) 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
AU2001295195B2 (en) * 2000-04-28 2007-02-01 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
HUP0301802A3 (en) * 2000-06-28 2009-04-28 Teva Pharma Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
EP1572966B1 (en) * 2002-10-18 2014-04-16 University of Florida Complete biosynthetic gene set for synthesis of polyketide antibiotics, including the albicidin family, resistance genes and uses thereof
JPWO2006109846A1 (ja) 2005-04-06 2008-11-20 武田薬品工業株式会社 トリアゾール誘導体およびその用途
US7758972B2 (en) * 2006-09-26 2010-07-20 Semiconductor Energy Laboratory Co., Ltd. Stilbene derivative, light emitting element, light emitting device, and electronic appliance
JP5379965B2 (ja) * 2006-09-26 2013-12-25 株式会社半導体エネルギー研究所 スチルベン誘導体、発光素子および発光装置
US8236983B2 (en) * 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
WO2008112941A1 (en) * 2007-03-13 2008-09-18 Board Of Regents The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
US8754124B2 (en) * 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
JP6474736B2 (ja) * 2013-02-15 2019-02-27 テヒーニィシエ ウニヴェルジテート ベルリン アルビシジン誘導体、その使用および合成
JP6730183B2 (ja) 2013-07-12 2020-07-29 ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ）
WO2015174747A1 (ko) 2014-05-15 2015-11-19 한국생명공학연구원 신규한 항균성 화합물 및 이의 용도
WO2016082934A1 (en) 2014-11-26 2016-06-02 Helmholtz-Zentrum für Infektionsforschung GmbH Novel cystobactamides

Also Published As

Publication number Publication date
EP3019615A2 (en) 2016-05-18
AU2014289663B2 (en) 2019-03-07
US10793600B2 (en) 2020-10-06
US20160145304A1 (en) 2016-05-26
CA2917767C (en) 2022-05-03
CN105793424A (zh) 2016-07-20
CA2917767A1 (en) 2015-01-15
WO2015003816A3 (en) 2015-03-12
US11225503B2 (en) 2022-01-18
WO2015003816A2 (en) 2015-01-15
US20190185514A1 (en) 2019-06-20
JP2016527215A (ja) 2016-09-08
CN105793424B (zh) 2021-02-19
EP3019615B1 (en) 2021-04-07
AU2014289663A1 (en) 2016-02-04
US20200331964A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
JP6730183B2 (ja) シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ）
Degrassi et al. Plant growth-promoting Pseudomonas putida WCS358 produces and secretes four cyclic dipeptides: cross-talk with quorum sensing bacterial sensors
CN113226297A (zh) 大麻素类似物及其制备方法
KR20120120287A (ko) 피리피로펜의 제조 방법
AU2004206046A1 (en) Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
Kook et al. Enhancement of γ-amminobutyric acid production by Lactobacillus sakei B2–16 expressing glutamate decarboxylase from Lactobacillus plantarum ATCC 14917
CN107001241B (zh) 新型孢囊菌酰胺
WO2012029811A1 (ja) リベロマイシンａまたはその合成中間体の製造法、スピロケタール環含有化合物の製造方法、並びに新規抗癌剤、抗真菌剤および骨疾患治療剤
US9630911B2 (en) Genes for biosynthesis of tetracycline compounds and uses thereof
CN104073507B (zh) 一种斑鸠霉素的生物合成基因簇及其应用
CN112391396B (zh) 构建于大肠杆菌中的粪肠球菌群体感应基因开关系统及其表达载体、工程菌和应用
KR101774940B1 (ko) 아스트린진 제조용 신규한 조성물
CN109797174B (zh) 一种氟苯尼考中间体的制备方法
HK1229840B (en) Cystobactamides
KR20010098713A (ko) 유전자 클러스터의 유전자
US9499825B2 (en) Dual inducible system for the condensed single protein production system
CN103205470A (zh) 一种短链脱氢酶TsrU的功能及其应用
KR101223665B1 (ko) 나이트릴레이즈 ｒｍｎ２을 이용한 카르복실산의 제조방법
KR101223663B1 (ko) 나이트릴레이즈 ｖｍｎ１을 이용한 카르복실산의 제조방법
KR101223666B1 (ko) 나이트릴레이즈 ｏｒｎ을 이용한 카르복실산의 제조방법
WO2009006492A2 (en) Stereoselective resolution of racemic amines
JP2003116567A (ja) 遺伝子クラスター
JP2002291476A (ja) ヒト上皮細胞増殖因子の製造法、および、該方法に使用する形質転換コリネ型細菌
CN110373371A (zh) 过表达木糖转运蛋白基因提高1,2,4-丁三醇产量的方法及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160715

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200702

R150 Certificate of patent or registration of utility model

Ref document number: 6730183

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250